Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 100%Moderate 0 · 0%High 0 · 0%

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Grades 3 and 4 adverse events · outpatients withmild disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.29 [0.75, 2.19]
1 study · 376 participants
Low

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Grades 3 and 4 adverse events · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.17 [0.96, 1.42]
6 studies · 2392 participants
Low

Sotrovimab vs placebo

Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Sotrovimab may leads to lower adverse events: grades 3 and 4 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.26 [0.12, 0.6]
1 study · 868 participants
Low

Regdanvimab vs placebo

Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Regdanvimab showed no clear difference in adverse events: grades 3 and 4 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 2.62 [0.52, 13.12]
1 study · 215 participants
Low

Bamlanivimab vs placebo

Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)

Bamlanivimab showed no clear difference in adverse events: grades 3 and 4 by day 30 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 1.27 [0.81, 1.98]
1 study · 314 participants
Low